Stockhub

Infant Bacterial Therapeutics AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

  • curprev 13:2813:28, 21 August 2022 >Nick 602 bytes +602 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants..."
Retrieved from "https://stockhub.co/research/Infant_Bacterial_Therapeutics_AB"